Results 51 to 60 of about 3,367,821 (256)

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo, Barbui, Tiziano, Beggiato, Eloise, Bellini, Marta, Bertozzi, Irene, Betti, Silvia, Bonifacio, Massimiliano, Cacciola, Emma, Cacciola, Rossella, Carli, Giuseppe, Carobbio, Alessandra, Cattaneo, Daniele, Cazzola, Mario, Censori, Bruno, Cervantes, Francisco, Cortelezzi, Agostino, De Stefano, Valerio, Di Lazzaro, Vincenzo, Elli, Elena Maria, Ellis, Martin H., Finazzi, Guido, Finazzi, Maria Chiara, Gaidano, Gianluca, Gomez, Montse, Griesshammer, Martin, Guglielmelli, Paola, Hernandez-Boluda, Juan-Carlos, Iurlo, Alessandra, Loscocco, Giuseppe Gaetano, Lunghi, Francesca, Miroslava, Palova, Musolino, Caterina, Palandri, Francesca, Randi, Maria Luigia, Rapezzi, Davide, Rossi, Elena, Rumi, Elisa, Sadjadian, Parvis, Scaffidi, Luigi, Tieghi, Alessia, Vannucchi, Alessandro M., Vianelli, Nicola   +41 more
core   +5 more sources

Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature

Annals of Saudi Medicine, 2016
Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative neoplasm. Chronic lymphocytic leukemia is a monoclonal expansion of a CD5+ CD19+ B lymphocytes.
Serdal Korkmaz, Sinan Kulakoglu, Hasan Gorkem, Bilal Aygun, Ali Cetinkaya   +4 more
doaj   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M, Fleischman, Angela G, Huynh, Christy, Morse, Sarah J, Nguyen, Hellen, Nguyen, Jenny, Nguyen, Thanh Kim   +6 more
core  

LNK (SH2B3): paradoxical effects in ovarian cancer. [PDF]

, 2015
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined
Chien, W, Ding, L-W, Doan, NB, Dong, X-M, Garg, M, Gery, S, Hattori, N, Huang, RY-J, Koeffler, HP, Lin, D-C, Liu, L-Z, Meng, X, Said, JW, Sun, Q-Y, Tang, K, Xiao, J-F, Yang, H   +16 more
core   +2 more sources

Case Report: Free-Floating Intracoronary Thrombus: Who Is the Convict?

Frontiers in Oncology, 2022
In young patients, especially with no traditional coronary risk factors, hypercoagulable states may always be considered as an alternative cause of acute coronary syndromes.
Francesca Mantovani, Ambra Paolini, Andrea Barbieri, Giuseppe Boriani   +3 more
doaj   +1 more source

Mouse models of myeloproliferative Neoplasms: JAK of all grades. (Review) [PDF]

, 2011
In 2005, several groups identified a single gain-of-function point mutation in the JAK2 kinase that was present in the majority of patients with myeloproliferative neoplasms (MPNs).
Li, J., Kent, D.G., Chen, E., Green, A.R., Li, J., Kent, D.G., Chen, E., Green, A.R.   +7 more
core   +2 more sources

Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. [PDF]

, 2008
Systemic mastocytoses represent neoplastic proliferations of mast cells. In about 20% of cases systemic mastocytoses are accompanied by clonal haematopoietic non-mast cell-lineage disorders, most commonly myeloid neoplasms.
Dirnhofer, S., Horny, H.-P., Jotterand, M., Muhlematter, D., Sotlar, Karl, Theocharides, A., Tzankov, A., Went, P.   +7 more
core   +1 more source

Erythromelalgia: An Uncommon Presentation Precipitated by Aspirin Withdrawal

Case Reports in Medicine, 2012
Erythromelalgia is a rare disorder frequently associated with myeloproliferative disorders. We describe a case of elderly patient diagnosed with myeloproliferative disorder in remission.
Fatima Khalid, Syed Hassan, Sophia Qureshi, Waqas Qureshi, Syed Amer   +4 more
doaj   +1 more source

Recurrent Episodes of Angioedema as Presenting Feature of JAK2-Positive Myeloproliferative Disorder Consistent with Polycythaemia Vera

European Medical Journal Hematology, 2021
Polycythaemia vera (PV) is one of the chronic myeloproliferative neoplasms, which are collectively characterised by clonal proliferation of myeloid cells with variable morphologic maturity and haematopoietic efficiency.
Laith Al-Azrai, Ala’a Abdullah Bani Mustafa, Adi Yousef al-Wahadneh   +2 more
doaj   +1 more source

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms

Advances in Hematology, 2012
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms.
Mar Bellido, Peter A. W. te Boekhorst
doaj   +1 more source